Study identifier:D8480C00054
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Multi-Centre, Open-Label, Dose Selection Study to Assess the Safety and Tolerability of Cediranib (RECENTIN™, AZD2171) in Combination with Etoposide and Cisplatin (EP) as First Line Therapy for Lung Cancer Patients with Extensive Stage or Metastatic Disease for Whom EP Would be a Standard Therapy
lung cancer
Phase 1
No
AZD2171, Etoposide, Cisplatin
All
62
Interventional
18 Years +
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
This study is to assess the safety and tolerability of Cediranib (RECENTIN™, AZD2171)in combination with etoposide and cisplatin (EP) as first line treatment for lung cancer patients with extensive stage or metastatic disease for whom EP would be a standard therapy.
Location
Location
Sacramento, CA, United States
Location
Denver, CO, United States
Location
Houston, TX, United States
Location
Kansas City, KS, United States
Arms | Assigned Interventions |
---|---|
Experimental: 1 | Drug: AZD2171 Oral Other Name: Recentin™ |
Active Comparator: 2 Etoposide + Cisplatin | Drug: Etoposide Intravenous Other Name: Etopophos® Drug: Cisplatin Intravenous Other Name: Platinol |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.